Abeona Therapeutics Inc.

OVERVALUEDABEO · NASDAQ · Healthcare
ABEO·NASDAQ·Healthcare
OVERVALUED
Abeona Therapeutics Inc.
25.5%downside
MARKET PRICE
$5.46
FAIR PRICE
$4.07
MARGIN
$1.39
UNDERVALUEDFAIROVERVALUED
P/E RATIO
5.3x
DIV. YIELD
N/A
ROE
53.2%
MARKET CAP
$305M
FPI
fairpriceindex.com

FAIR PRICE VALUATION

25.5%downside

Updated daily

Model: DCF 50% · Relative 30% · Consensus 20%

MARKET PRICE

$5.46

FAIR PRICE

$4.07

MARGIN

$1.39

UNDERVALUEDFAIROVERVALUED

P/E Ratio

5.3x

What is P/E? →

Div. Yield

N/A

ROE

53.2%

Exceptional

Market Cap

$305M

Small-cap

NOW AVAILABLE

Get notified when ABEO's fair price changes

Push notifications when ABEO's valuation shifts. Available on iOS and Android.

Download on the App StoreGet it on Google Play

FPI RATING

4.5/ 10

Low debt levels and attractive valuation, but volatile earnings pattern and limited growth momentum.

Analytical data, not an investment recommendation. Updated daily.

How we calculate this ↗

MARGIN OF SAFETY

A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.

$3.26CONSERVATIVE ENTRY
$4.07FAIR PRICE
$5.46MARKET PRICE

SAFETY MARGIN

20%

Below fair value

ENTRY LEVEL

$3.26

Fair price × 0.80

DISTANCE

40.4%

Price to entry level

At the current price of $5.46, ABEO trades 40.4% above the conservative entry level of $3.26. This entry level represents a 20% margin of safety below the calculated fair price of $4.07 — a buffer that accounts for estimation uncertainty in the valuation model.

Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗

VALUATION HISTORY

Loading chart data...

P/E RATIO HISTORY

Loading chart data...

METHODOLOGY

How we calculate ABEO's fair price

Abeona Therapeutics Inc.'s fair price of $4.07 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $5.46, ABEO trades 25.5% above its calculated fair value.

DCF MODEL · 50%

Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting ABEO's risk profile.

RELATIVE · 30%

Comparing ABEO's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.

ANALYST · 20%

Aggregated analyst price targets for ABEO, weighted by recency and analyst accuracy.

TRY IT YOURSELF

Want to test your own assumptions? Use our free calculators to estimate ABEO's fair value with your own inputs.

LEARN MORE

Bulios

POWERED BY BULIOS

Get full analysis, financials, and AI insights for ABEO.

Explore on Bulios

FAQ

What is the fair price of ABEO?+

Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Abeona Therapeutics Inc. is $4.07. At the current market price of $5.46, ABEO trades 25.5% above its calculated fair value.

Is ABEO overvalued or undervalued?+

Abeona Therapeutics Inc. is currently overvalued based on our valuation model. The stock trades at $5.46, which is 25.5% above the fair price of $4.07. The P/E ratio of 5.3x is a key metric in the valuation.

What is the margin of safety for ABEO?+

With a 20% margin of safety applied to the fair price of $4.07, the conservative entry level for ABEO is $3.26. At the current market price of $5.46, the stock trades 40.4% above this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.

How often is ABEO's fair price updated?+

We update fair price calculations for ABEO daily after market close. The current fair price of $4.07 incorporates the latest market data and sector multiples.

What factors affect ABEO's fair price calculation?+

ABEO's fair price of $4.07 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight). Key metrics include P/E of 5.3x, ROE of 53.2%.

Is ABEO a good buy right now?+

At $5.46, ABEO trades 25.5% above our fair value estimate of $4.07. The stock is currently overvalued. ROE stands at 53.2% (exceptional). Fair Price Index provides valuation data — always do your own research before investing.

Does ABEO pay dividends?+

ABEO does not currently pay a dividend.

RELATED STOCKS

Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.